- €49.21bn
- €48.90bn
- €7.74bn
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside
Brief: UCB Says CIMZIA Delivered Consistent Effect In Rheumatoid Arthritis
Brief: UCB Said Dapirolizumab Pegol Shows Potential To Reduce Flare Rates
Brief: UCB Presents Bimzelx Data At Eular 2026
Brief: UCB Completes $1.15 Bln Acquisition Of Neurona Therapeutics
Brief: UCB And Biogen Announce Positive DZP Phase 3 Study Results
Brief: UCB's Bimzelk Demonstrates Superior Efficacy Over Skyrizi(Risankizumab) In Psoriatic Arthritis
Brief: UCB: New Partnership With Cancer Research UK And Cancer Research Horizons
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Rallybio jumps as UCB steps in with $2.2 bln deal for Candid
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
UCB falls on Novartis' results read-across
Belgium's UCB to acquire Neurona Therapeutics for up to $1.15 billion (updated)
Belgium's UCB to acquire Neurona Therapeutics for up to $1.15 billion